Horizon Therapeutics has enrolled the first patient into its Phase 2 study to evaluate the safety and efficacy of daxdilimab for treatment of active lupus nephritis (LN, lupus-related kidney disease).

Daxdilimab is an antibody-based therapy designed to reduce plasmacytoid dendritic cells (pDCs), a type of immune cell in the body. More than 200 people with LN will be enrolled in the study and their kidney response to the treatment will be monitored. The therapy is also being explored for other autoimmune conditions.

Continue to follow the Lupus Foundation of America for daxdilimab updates, as well as other lupus drug development news, and learn about medications used to treat lupus.

Read the announcement